rs200314808
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 3P and 1B. PM2PP2BP4
The NM_015915.5(ATL1):c.196G>A(p.Glu66Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,614,064 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E66Q) has been classified as Likely benign.
Frequency
Consequence
NM_015915.5 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 3AInheritance: AD, SD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
 - neuropathy, hereditary sensory, type 1DInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae)
 - hereditary sensory and autonomic neuropathy type 1Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| ATL1 | NM_015915.5  | c.196G>A | p.Glu66Lys | missense_variant | Exon 2 of 14 | ENST00000358385.12 | NP_056999.2 | |
| ATL1 | NM_001127713.1  | c.196G>A | p.Glu66Lys | missense_variant | Exon 3 of 14 | NP_001121185.1 | ||
| ATL1 | NM_181598.4  | c.196G>A | p.Glu66Lys | missense_variant | Exon 2 of 13 | NP_853629.2 | ||
| ATL1 | XM_047431430.1  | c.196G>A | p.Glu66Lys | missense_variant | Exon 3 of 15 | XP_047287386.1 | 
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.00000657  AC: 1AN: 152172Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.00000398  AC: 1AN: 251478 AF XY:  0.00000736   show subpopulations 
GnomAD4 exome  AF:  0.00000274  AC: 4AN: 1461892Hom.:  0  Cov.: 32 AF XY:  0.00000550  AC XY: 4AN XY: 727248 show subpopulations 
Age Distribution
GnomAD4 genome   AF:  0.00000657  AC: 1AN: 152172Hom.:  0  Cov.: 32 AF XY:  0.00  AC XY: 0AN XY: 74352 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
Hereditary spastic paraplegia 3A    Uncertain:1 
This sequence change replaces glutamic acid with lysine at codon 66 of the ATL1 protein (p.Glu66Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with ATL1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at